TXNDC5 and central nervous system cancer: Our analysis revealed that tumors with high progressive capacity have elevated levels of TXNDC5 in LGG (Figure 5J) and all grade glioma (Figure 5L) patients while TXNDC5 expression did not change with progressive phenotype in GBM group (Figure 5K).